Who is sponsoring NCT03331523?

NCT03331523 is sponsored by Glenmark Pharmaceuticals Ltd. India.

What drugs are being tested in NCT03331523?

Interventions in NCT03331523: Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo.

What condition does NCT03331523 study?

NCT03331523 studies Scalp Psoriasis.

Is NCT03331523 still recruiting?

NCT03331523 is currently completed. Last updated 21 December 2018.

Last reviewed 2018-12-21 · How we verify

NCT03331523

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

Completed Phase 3 Last updated 21 December 2018

What this trial tests

Phase 3 trial testing Calcipotriene/Betamethasone Dipropionate in Scalp Psoriasis in 643 participants. Completed in 25 October 2018.

Timeline

20 October 2017

Primary endpoint
25 October 2018

25 October 2018

Quick facts

Lead sponsor	Glenmark Pharmaceuticals Ltd. India
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	643
Start date	20 October 2017
Primary completion	25 October 2018
Estimated completion	25 October 2018
Sites	31 locations across United States

Drugs / interventions tested

Calcipotriene/Betamethasone Dipropionate
Taclonex®
Placebo

Conditions studied

Scalp Psoriasis — all drugs for Scalp Psoriasis →

Sponsor

Glenmark Pharmaceuticals Ltd. India — full company profile →

Who can join

18 and older, any sex, with Scalp Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase III, randomized, double-blind, placebo-controlled, parallel- group, multiple-site study to evaluate the therapeutic equivalence of generic calcipotriene and betamethasone dipropionate topical suspension, 0.005%/0.064% of Glenmark Pharmaceuticals Ltd to that of the marketed product Taclonex® topical suspension of Leo Pharma Inc. in the treatment of scalp psoriasis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Glenmark Pharmaceuticals Ltd. India trials

Trials by the same sponsor.

NCT05363202 — To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma · Phase 3 · unknown
NCT03731091 — To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis · Phase 3 · completed
NCT03444506 — Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Mol · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03331523 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Glenmark Pharmaceuticals Ltd. India
Last refreshed: 21 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03331523.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing